CMA reimposes excessive pricing fines on Pfizer and Flynn
The UK’s Competition and Markets Authority has collectively fined drugmakers Pfizer and Flynn Pharma nearly £70 million after an appellate court ordered it to reassess its original decision to punish the companies for excessively pricing a lifesaving anti-epilepsy drug.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.